The Technical Analyst
Precipio Inc [PRPO]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Precipio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-7.74% $6.20
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8.51 mill |
| EPS: | -4.51 |
| P/E: | -1.370 |
| Earnings Date: | May 15, 2024 |
| SharesOutstanding: | 1.373 mill |
| Avg Daily Volume: | 0.0051 mill |
| RATING 2024-04-19 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.370 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -1.370 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 5.90 - 6.51 ( +/- 4.92%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Laporte Kathleen | Buy | 9 693 | Common Stock |
| 2024-04-15 | Sandberg Richard A | Buy | 5 913 | Common Stock |
| 2024-04-15 | Cossman Jeffrey | Buy | 8 143 | Common Stock |
| 2024-04-15 | Cohen David Seth | Buy | 3 575 | Common Stock |
| 2024-04-15 | Andrews Ronald Asbury | Buy | 3 153 | Common Stock |
| INSIDER POWER |
|---|
| 99.42 |
| Last 96 transactions |
| Buy: 2 731 117 | Sell: 221 280 |
Forecast:
14:07 - $6.20
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $6.20 (-7.74% ) |
| Volume | 0.0016 mill |
| Avg. Vol. | 0.0051 mill |
| % of Avg. Vol | 32.17 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PRPO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PRPO
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Last 10 Buy Signals
Latest Press Releases
2024-03-25 17:00:00 - Press Release
Precipio Announces Year End 2023 Shareholder Update Call
New haven, conn., march 25, 2024 (globe newswire) -- specialty cancer diagnostics company precipio, inc. (nasdaq: prpo), will be hosting its year end 2023 corporate update call on april 1st, 2024 at 5:00 pm et.
2024-02-13 10:00:00 - Press Release
Precipio To Report $15.2m For Fy-2023 (unaudited) Revenues, An Increase Of 60% Yoy
New haven, conn., feb. 13, 2024 (globe newswire) -- specialty cancer diagnostics company precipio, inc. (nasdaq: prpo) , announces that for the full year of 2023, its unaudited revenues have grown from $9.4m in 2022 to $15.2m in 2023, an increase of 60% year over year.
2024-02-06 10:00:00 - Press Release
Precipio And Cardinal Health Sign Distribution Agreement For Its Hemescreen® Portfolio Of Molecular Assays For Cancer
New haven, conn., feb. 06, 2024 (globe newswire) -- specialty cancer diagnostics company precipio, inc. (nasdaq: prpo) announces it has entered into a distribution agreement with cardinal health for its hemescreen molecular assay products.
2024-01-23 10:00:00 - Press Release
Precipio's Q4-2023 Cash Burn From Operations (unaudited) Drops Below $100k For The Full Quarter
Results clearly demonstrate the business's ability to reach breakeven in the near future results clearly demonstrate the business's ability to reach breakeven in the near future
2024-01-17 10:30:00 - Press Release
Precipio Signs Distribution Agreement For Iv-cell® And Hemescreen® In Japan
New haven, conn., jan. 17, 2024 (globe newswire) -- specialty cancer diagnostics company precipio, inc. (nasdaq: prpo) announces it has entered into an agreement with a japanese distributor for the sales and distribution of its products into the japanese market.
Latest News
2024-02-13 10:00:00 - GlobeNewsWire
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for the full year of 2023, its unaudited revenues have grown from $9.4M in 2022 to $15.2M in 2023, an increase of 60% year over year.
2023-11-20 18:38:08 - Seeking Alpha
Precipio, Inc. (PRPO) Q3 2023 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q3 2023 Earnings Conference Call November 20, 2023 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Operator Welcome to the Precipio Third Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode.
2023-10-18 09:00:00 - GlobeNewsWire
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022
NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from Q3-2022.
2023-08-17 18:32:03 - Seeking Alpha
Precipio, Inc. (PRPO) Q2 2023 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q2 2023 Earnings Conference Call August 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Second Quarter 2023 Shareholder Update Conference Call. All participants will be in listen-only mode.
2023-05-18 12:34:04 - Seeking Alpha
Precipio, Inc. (PRPO) Q1 2023 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q1 2023 Earnings Conference Call May 17, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio Q1 2023 Shareholder Update Conference Call. All participants will be in listen-only mode.
2023-04-03 19:10:04 - Seeking Alpha
Precipio, Inc. (PRPO) Q4 2022 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q4 2022 Earnings Conference Call April 3, 2023 5:00 PM ET Company Participants Ilan Danieli - CEO Conference Call Participants Operator Welcome to the Precipio shareholder 2022 Fourth Quarter and Year-End Shareholder Update Conference Call. All participants will be in listen-only mode.
2022-11-14 18:37:05 - Seeking Alpha
Precipio, Inc. (PRPO) Q3 2022 Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Conference Call Participants Operator Welcome to the Precipio Shareholder Third Quarter 2022 Shareholder Update Conference Call. All participants will be in listen-only mode.
2022-08-15 20:24:13 - Seeking Alpha
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2022 Results - Earnings Call Transcript
Precipio, Inc. (NASDAQ:PRPO ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Ilan Danieli - Founder, President, CEO & Director Conference Call Participants Operator Welcome to the Precipio Shareholder -- Second Quarter 2022 Shareholder Update Conference Call. (Operator Instructions) Please note that the conference is being recorded.
2022-04-26 10:00:00 - GlobeNewsWire
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , is excited to announce its participation and the presentation of HemeScreen, its novel diagnostic technology platform, at the Executive War College , organized by publication Dark Daily, the premier laboratory conference, held April 26th through 28th in New Orleans.
2022-04-04 19:30:21 - Seeking Alpha
Precipio, Inc. (PRPO) CEO Ilan Danieli on Q4 2021 Results - Earnings Call Transcript
